{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:59:00Z","timestamp":1770901140645,"version":"3.50.1"},"reference-count":52,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,12,11]],"date-time":"2006-12-11T00:00:00Z","timestamp":1165795200000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:p><jats:bold><jats:sc>Abstract:\u2002<\/jats:sc><\/jats:bold>  <jats:bold>Breast cancer has the highest incidence of all types of cancer in women. Age and family history are the strongest risk factors, but sex hormones also play an important role, as demonstrated by epidemiological studies reporting a consistent association by reproductive personal history and breast cancer risk. The acceptability of preventive strategies by healthy women is closely related to their lifetime risk of developing breast cancer. Although surgical prevention may be considered in carriers of BRCA1\/2 mutation, this option cannot be advocated for the majority of women whose risk is only moderately increased. In these women, chemoprevention with tamoxifen may reduce the incidence of estrogen receptor (ER)\u2010positive breast carcinoma by 30\u201350%. Other drugs such as raloxifen and aromatase inhibitors (AIs) are currently being tested in this setting. Tamoxifen has been the most successful hormonal treatment over the last 30 years and, until recently, the most active drug in endocrine\u2010sensitive breast cancer. In premenopausal breast cancer, tamoxifen still represents the therapy of choice, alone or in association with ovarian suppression. Conversely, in postmenopausal women it has been overtaken by third\u2010generation AIs as first\u2010choice drugs both in the adjuvant and metastatic settings. Many other issues, such as the optimal sequence between tamoxifen and AIs, the duration of AIs treatment, and the association of ovarian suppression and AIs in premenopausal patients still await the completion of randomized clinical trials. Furthermore, it is likely that treatment tailoring will be increased by the definition of patient subgroups that could derive larger benefits from AIs (progesterone receptor\u2013negative, HER\u20102\u2010overexpressing) or other new drugs.<\/jats:bold> <\/jats:p>","DOI":"10.1196\/annals.1386.037","type":"journal-article","created":{"date-parts":[[2007,2,2]],"date-time":"2007-02-02T18:28:39Z","timestamp":1170440919000},"page":"143-158","source":"Crossref","is-referenced-by-count":22,"title":["Antihormones in Prevention and Treatment of Breast Cancer"],"prefix":"10.1111","volume":"1089","author":[{"given":"RICCARDO","family":"PONZONE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NICOLETTA","family":"BIGLIA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARIA ELENA","family":"JACOMUZZI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LUCA","family":"MARIANI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ANNELISE","family":"DOMINGUEZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PIERO","family":"SISMONDI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,12,11]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.56.3.168"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7168.1307"},{"key":"e_1_2_5_4_2","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.1988.03410050072032","article-title":"A meta\u00adanalysis of alcohol consumption in relation to risk of breast cancer","volume":"260","author":"Longnecker M.P.","year":"1988","journal-title":"JAMA"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.18.1541"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-5-200509060-00012"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.028"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1200\/JCO.2005.10.035","article-title":"Prevention and management of hereditary breast cancer","volume":"23","author":"Narod S.A.","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.3.150"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)11423-4"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17666-6"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)85012-5"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04394-3"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.18.1371"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09962-2"},{"key":"e_1_2_5_16_2","first-page":"296","volume":"361","author":"Cuzick J.","year":"2003","journal-title":"Overview of the main outcomes in breast-cancer prevention trials. Lancet"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90127-0"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.7.637"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh319"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.23.joc60074"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062462"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040331"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052258"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.120"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67059-6"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032312"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-55647-0_9"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.20.2433"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2004.n.006"},{"key":"e_1_2_5_30_2","first-page":"2343","article-title":"Selective cyclooxygenase (COX)\u20101 or COX\u20102 inhibitors control metastatic disease in a murine model of breast cancer","volume":"62","author":"Kundu N.","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-200607000-00011"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)72307-0"},{"key":"e_1_2_5_33_2","first-page":"1980","article-title":"The estrogen receptor: a model for molecular medicine","volume":"9","author":"Jensen E.V.","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392207"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66544-0"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.9.684"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.05.042"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg119"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1054\/brst.2002.0451"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.2.343"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.14.2718"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.09.112"},{"key":"e_1_2_5_43_2","first-page":"72a","article-title":"Complete hormonal blockade versus chemotherapy in premenopausal early\u2010stage breast cancer patients (pts) with positive hormone\u2010receptor (HR+) and 1\u20103 node\u2010positive (N+) tumor: results of the FASG 06 trial [abstr 279]","volume":"19","author":"Roch\u00e9 H.H.","year":"2000","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_2_5_44_2","first-page":"5","article-title":"Chemohormonal therapy in premenopausal node\u2010positive, receptor\u2010positive breast cancer: an Eastern Cooperative Oncology Group phase III intergroup trial (E5188,INT\u20100101) [abstr 15]","volume":"22","author":"Davidson N.E.","year":"2003","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_2_5_45_2","first-page":"67a","article-title":"Zoladex and tamoxifen as adjuvant therapy in premenopausal breast cancer: a randomized trial by the Cancer Research Campaign (C.R.C.) Breast Cancer Trials Group, the Stockholm Breast Cancer Study Group, the South\u2010East Sweden Breast Cancer Group & the Gruppo Interdisciplinare Valutazione Interventi in Oncologia (G.I.V.I.O) [abstr 251]","volume":"18","author":"Rutqvist L.E.","year":"1999","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.11.050"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y"},{"key":"e_1_2_5_48_2","first-page":"6","article-title":"First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)\u2014a randomized phase III trial of the EORTC Breast Group","volume":"23","author":"Paridaens R.","year":"2004","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.194"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052258"},{"issue":"1","key":"e_1_2_5_51_2","first-page":"27","article-title":"Effect of anastrozole on bone mineral density: 2\u2010year results of the Arimidex (anastrozole), tamoxifen, alone or in combination (ATAC) trial","volume":"82","author":"Howell A.","year":"2003","journal-title":"Breast Cancer Res. Treat."},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.4829"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3808"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1386.037","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1386.037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T01:32:53Z","timestamp":1695605573000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1386.037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1196\/annals.1386.037"],"URL":"https:\/\/doi.org\/10.1196\/annals.1386.037","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}